These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17522409)

  • 21. DPP-4 inhibitors in clinical practice.
    Palalau AI; Tahrani AA; Piya MK; Barnett AH
    Postgrad Med; 2009 Nov; 121(6):70-100. PubMed ID: 19940419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
    Ahrén B
    Vasc Health Risk Manag; 2008; 4(2):383-94. PubMed ID: 18561513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
    Montilla S; Marchesini G; Sammarco A; Trotta MP; Siviero PD; Tomino C; Melchiorri D; Pani L;
    Nutr Metab Cardiovasc Dis; 2014 Dec; 24(12):1346-53. PubMed ID: 25300980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DPP4 inhibitors: a new approach in diabetes treatment.
    Doupis J; Veves A
    Adv Ther; 2008 Jul; 25(7):627-43. PubMed ID: 18641927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
    Gupta R; Walunj SS; Tokala RK; Parsa KV; Singh SK; Pal M
    Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New treatments for type 2 diabetes--the DPP4 inhibitors.
    Gadsby R
    Prim Care Diabetes; 2007 Dec; 1(4):209-11. PubMed ID: 18632049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
    Fakhoury WK; Lereun C; Wright D
    Pharmacology; 2010; 86(1):44-57. PubMed ID: 20616619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DPP-4 inhibitors: what may be the clinical differentiators?
    Gerich J
    Diabetes Res Clin Pract; 2010 Nov; 90(2):131-40. PubMed ID: 20708812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
    Ahrén B
    Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
    [No Abstract]   [Full Text] [Related]  

  • 31. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
    Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
    Aschner P; Kipnes MS; Lunceford JK; Sanchez M; Mickel C; Williams-Herman DE;
    Diabetes Care; 2006 Dec; 29(12):2632-7. PubMed ID: 17130196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
    Davidson JA; Parente EB; Gross JL
    Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):1039-49. PubMed ID: 18820816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New concepts in the treatment of type 2 diabetes].
    Meier JJ; Schmidt WE; Klein HH
    Internist (Berl); 2007 Jul; 48(7):698, 700-7. PubMed ID: 17541529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
    Jermendy G
    Orv Hetil; 2011 Sep; 152(37):1471-6. PubMed ID: 21893477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.
    Wani JH; John-Kalarickal J; Fonseca VA
    Cardiol Clin; 2008 Nov; 26(4):639-48. PubMed ID: 18929237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.
    Nicolucci A; Rossi MC
    Acta Biomed; 2008 Dec; 79(3):184-91. PubMed ID: 19260377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.